Category Archives: Parkinson’s Treatment

WATCH TIME: 6 minutes "When we think about rapid progressive dementia, it is a big category. One thing that we've learned from our experience enrolling patients and assessing them is that if you take all comers, including inpatients and outpatients, there's a sizable proportion of patients that have a potentially treatment responsive because of rapid progressive dementia." Rapidly progressive dementias (RPDs) are a collection of different heterogeneous diseases that include encephalopathies and atypically rapid presentations of more common neurodegenerative diseases. Researchers note that some of these conditions are treatable, although others require prompt diagnosis because of their potential infectivity.1 Gregory Day, MD, MSc, MSCI, FAAN, gave a talk on RPD in a seminar dedicated to aging, dementia, cognitive, and behavioral neurology at the 2023 American Academy of Neurology (AAN) Annual Meeting, April 22-27, in Boston, Massachusetts Continue reading →

Parkinson's causes uncontrollable tremors that are the most well known symptom of the disease, but there are other early signs you might not know. Symptoms of Parkinson's disease usually begin gradually and worsen over time Continue reading →

BETHESDA, Md., May 03, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced that Innosuisse, the Swiss Innovation Agency, supports GT Gain Therapeutics SA with the amount of CHF 2.5 million (~$2.8 million) to develop GT-02287, Gains lead program for GBA1 Parkinsons disease. The Companys Swiss Accelerator innovation project supported by Innosuisse entitled Harnessing Structurally Targeted Allosteric Regulators to treat Parkinsons Disease includes clinical pharmacology and preclinical studies with the Companys drug candidate GT-02287, which will be conducted as the lead program progresses through Phase 1 and Phase 2 clinical studies in GBA1 Parkinsons disease Continue reading →

Texas Public Radio will partner with UT Health San Antonio to serve the community at the next Think Science live program, sharing the latest information about the connections between brain and body health and new developments in the fight against dementia and Alzheimers disease. Continue reading →

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Parkinson's Disease pipeline constitutes key companies continuously working towards developing Parkinson's Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. Continue reading →

WATCH TIME: 5 minutes Everyone could [sit at] the table, and have [a] discussion about what are the possible issues with diversity, equity, and inclusion and systematic barriers to advancement for faculty, entry into the practice of neurology for residents and students, and then that may impact the patient care for the community that we care for. At the 2023 American Academy of Neurology (AAN) Annual Meeting, held April 22-27, in Boston, Massachusetts, a group of clinicians from Montefiore Health System presented an abstract that shared the experience of establishing a neurology department diversity, equity, and inclusion (DEI) committee. Continue reading →

Adults and children with cognitive disorders may have trouble walking but neurologic music therapy can be a helpful part of their treatment plan, according to growing research. Continue reading →

Researchers have characterized the brain complications caused by COVID-19 in people with dementia. Continue reading →

GOTHENBURG, SWEDEN / ACCESSWIRE / May 3, 2023 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, May 3, 2023 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company that discovers and develops new treatments for Parkinson's disease, announced today that IRLAB has been made aware that Ipsen's 2022 Universal Registration Document, published on April 6, 2023, contains incorrect information that the development and commercialization rights for mesdopetam have been transferred back to IRLAB. This is not correct. Collaborative discussions regarding mesdopetam's further development path are ongoing Continue reading →

The Andrews University Speech-Language & Hearing Clinic was recently awarded a SPEAK OUT! Therapy and Research Center Grant by the Parkinson Voice Project. The Andrews University Speech-Language & Hearing Clinic was recently awarded a SPEAK OUT! Therapy and Research Center Grant by the Parkinson Voice Project. Valued at more than $280,000, the award provides extensive training and services offered by the nonprofit Parkinson Voice Project over the next five years, including $10,000 per year for resources over the same period Continue reading →